[go: up one dir, main page]

ES2092568T3 - Identificacion de nuevos farmacos y reactivos. - Google Patents

Identificacion de nuevos farmacos y reactivos.

Info

Publication number
ES2092568T3
ES2092568T3 ES91910623T ES91910623T ES2092568T3 ES 2092568 T3 ES2092568 T3 ES 2092568T3 ES 91910623 T ES91910623 T ES 91910623T ES 91910623 T ES91910623 T ES 91910623T ES 2092568 T3 ES2092568 T3 ES 2092568T3
Authority
ES
Spain
Prior art keywords
reagents
identification
new drugs
nucleic acid
infectious agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91910623T
Other languages
English (en)
Inventor
Christopher K Mirabelli
Timothy Vickers
David J Ecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2092568T3 publication Critical patent/ES2092568T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)

Abstract

SE DESCRIBEN METODOS PARA IDENTIFICAR OLIGONUCLEOTIDOS CAPACES DE HIBRIDIZARSE CON EL ACIDO NUCLEICO DE UN AGENTE INFECCIOSO. DE ACUERDO CON LAS REALIZACIONES PREFERIDAS, SE IDENTIFICAN LOS OLIGONUCLEOTIDOS CAPACES DE UNA INTERACCION INVERSA CON EL ARN QUE ES SIGNIFICATIVA RESPECTO A UN ESTADO CORPORAL DE UN ANIMAL O QUE CONTRIBUYE A UN ESTADO DE ENFERMEDAD. SE SUMINISTRAN METODOS TERAPEUTICOS, DE DIAGNOSTICO Y DE INVESTIGACION Y COMPOSICIONES EN LOS QUE SE UTILIZAN TALES OLIGONUCLEOTIDOS. NO SE SUELE NECESITAR LA TECNICA ANTERIOR DE LA SECUENCIA DEL ACIDO NUCLEICO DEL AGENTE INFECCIOSO.
ES91910623T 1990-05-01 1991-04-15 Identificacion de nuevos farmacos y reactivos. Expired - Lifetime ES2092568T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51724090A 1990-05-01 1990-05-01

Publications (1)

Publication Number Publication Date
ES2092568T3 true ES2092568T3 (es) 1996-12-01

Family

ID=24058975

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91910623T Expired - Lifetime ES2092568T3 (es) 1990-05-01 1991-04-15 Identificacion de nuevos farmacos y reactivos.

Country Status (10)

Country Link
EP (1) EP0527941B1 (es)
JP (1) JP2706568B2 (es)
AT (1) ATE143056T1 (es)
AU (1) AU7974791A (es)
CA (1) CA2081984A1 (es)
DE (1) DE69122246T2 (es)
DK (1) DK0527941T3 (es)
ES (1) ES2092568T3 (es)
GR (1) GR3021418T3 (es)
WO (1) WO1991017266A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2082411A1 (en) * 1991-06-28 1992-12-29 Robert D. Rosenberg Localized oligonucleotide therapy
JP3190042B2 (ja) * 1991-10-31 2001-07-16 マトリテク インコーポレイテッド 核マトリックス蛋白液アッセー
CA2138807A1 (en) * 1992-06-22 1994-01-06 Gary Toukatly Novel malignant cell type markers of the interior nuclear matrix
JP3231098B2 (ja) * 1992-10-16 2001-11-19 浜松ホトニクス株式会社 植物の病害抵抗性検定方法および装置、病害抵抗性付与能力の評価方法および装置、農薬の評価方法および装置
US5919647A (en) * 1992-10-16 1999-07-06 Hamamatsu Photonics K.K. Methods and apparatuses for examining pathogen resistance of plant, for evaluating ability to impart pathogen resistance to plant, and for evaluating agricultural chemical
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6455247B1 (en) 1996-01-23 2002-09-24 Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules

Also Published As

Publication number Publication date
JP2706568B2 (ja) 1998-01-28
DK0527941T3 (da) 1996-10-07
CA2081984A1 (en) 1991-11-02
DE69122246T2 (de) 1997-02-06
AU7974791A (en) 1991-11-27
EP0527941A4 (es) 1994-04-27
WO1991017266A1 (en) 1991-11-14
EP0527941A1 (en) 1993-02-24
JPH05505529A (ja) 1993-08-19
ATE143056T1 (de) 1996-10-15
GR3021418T3 (en) 1997-01-31
DE69122246D1 (de) 1996-10-24
EP0527941B1 (en) 1996-09-18

Similar Documents

Publication Publication Date Title
NO970041D0 (no) Pattedyr-telomerase
DE3875667D1 (de) Menschliche papillomavirusnukleinsaeureproben.
DE69433626D1 (de) N-2 substituierte purine
PT89050A (pt) Meios e metodo para intensificar a hibridacao de acidos nucleicos
ATE145248T1 (de) Schnellverfahren zum nachweis und/oder zur identifizierung einer einzelbase in einer nukleinsäuresequenz und seine verwendungen
FI970656A (fi) Painonsäätelyaineet, vastaavat nukseiinihapot ja proteiinit ja näiden diagnostiset ja terapeuttiset käytöt
DE59509908D1 (de) Vorfüllbare partikelarme, sterile Einmalspritze für die Injektion von Präparaten und Verfahren zu ihrer Herstellung
NO873753D0 (no) Periodisk biologisk luftbehandlingsprosess og system for denne.
FR2703693B1 (fr) Procédé rapide de détermination d'une séquence d'ADN et application au séquençage et au diagnostic.
DE3583564D1 (de) Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
WO1996001614A3 (en) Rna component of telomerase
ES2092568T3 (es) Identificacion de nuevos farmacos y reactivos.
ID27442A (id) Oligonukleotida untuk amplifikasi dan deteksi asam inti sel epstein barr (ebv)
FR2651505B1 (fr) Fragments d'acides nucleiques derives d'un genome de mycobacterie appropriee, leurs applications dans le diagnostic des infections a mycobacteries et plasmides contenant lesdits fragments.
DE69836485D1 (de) Hepatitis e-virus aus dem schwein und dessen verwendungen
FI892769L (fi) Foerfarande foer inaktivering av den rekombinanta dna:n.
ATE119206T1 (de) Dmd-sonden.
ATE403716T1 (de) Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
DK727688A (da) Malariaspecifikke dna-sekvenser, deres expressionsprodukter samt anvendelsen heraf
FI884069A0 (fi) Diagnos och behandling av bristtillstaond pao dubbelstraengat rna.
NO875058L (no) Oligonukleotidprober og fremgangsmÿte for detektering av nukleinsyrene i bakterier og andre levende organismer ved hybridisering.
KR940012633U (ko) 핵산(dna) 증폭 배양기
ATE82021T1 (de) Menschliche papillomavirusnukleinsaeureproben.
NO890265D0 (no) Biologisk diagnostisk analysesystem.
FR2706128B1 (fr) Procédé de préparation de déjections animales, déjections animales désodorisées et leur utilisation .

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 527941

Country of ref document: ES